In recent weeks, Merck secured new regulatory milestones for its KEYTRUDA franchise, including U.S. FDA approval for KEYTRUDA and KEYTRUDA QLEX with paclitaxel, with or without bevacizumab, in PD-L1+ ...

Merck (MRK) is back in focus after Health Canada cleared KEYTRUDA SC, a subcutaneous version of its flagship cancer therapy, alongside a new AI-focused drug discovery partnership with Mayo Clinic that ...

Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can ...

Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.

Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. Health Canada has approved Keytruda ...

Merck & Co., Inc. (NYSE:MRK) is one of the best immunotherapy stocks to buy according to hedge funds. On February 13, Merck & Co., Inc. (NYSE:MRK) was upgraded to Buy from Hold by Deutsche Bank, with ...

Merck to present data across multiple genitourinary cancers from several approved and investigational medicines at 2026 ASCO GU cancers symposium: Rahway, New Jersey Saturday, Feb ...

ImmunityBio Executive Chairman Patrick Soon-Shiong criticized the FDA for applying tougher approval standards to Anktiva than ...

A former NASA senior executive and engineer, Smith is leading a team developing low-orbit space stations that will ...

Merck & Co. Inc. stock reached a 52-week high, closing at $122.69. This milestone highlights a significant upward trend for the pharmaceutical giant, marking a notable recovery and growth over the ...

Bristol-Myers Squibb Company hits a 52-week high as Breyanzi sales surge and AI imaging expands. Click for this updated look at BMY stock prospects.